Insider buying
~$238247 sh @ $0.962
First insider buy since Sep 2022Traded Dec 30, 2025 · filed the same day
Since the trade −58.5% · S&P 500 +7.7% · to Nov 16
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
MBIO · NASDAQ · Pharmaceutical Preparations
Mustang Bio (MBIO) · oqro.io/stocks/MBIO · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.3947−0.0267 (−6.34%)
Close of Nov 16, 2026, vs Nov 13 · end-of-day, not a live quote
No open-market purchase by an insider of Mustang Bio was filed in the last 90 days. The latest on record was on Dec 30, 2025.
Since 2018, Mustang Bio insiders reported 23 open-market purchases and 12 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2025.
No open-market sale by an insider of Mustang Bio (MBIO) was filed with the SEC in the last 90 days.
No trade in Mustang Bio (MBIO) was disclosed by a member of Congress in the last 12 months.
Mustang Bio's next results are expected on Mar 17, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−66.0% (−$0.7653) from Nov 17, 2025 to Nov 16, 2026 · adjusted daily closes
Adjusted close went from $1.16 on Nov 17, 2025 to $0.3947 on Nov 16, 2026 (−66.0%). Disclosed in this range: 3 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Waltham, Ma.
Last 12 months
−67.7%
Market value
$2.99M
S&P 500 +10.1% over the same dates. Prices adjusted for splits and dividends.
Short interest: 70K shares sold short (0.9% of shares outstanding), +19.3% vs the previous count, 2.8 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $14.3M, at Sep 30, 2026
Net income, last 12 months
−$3.53M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Apr 29, 2024.
Insider buying
First insider buy since Sep 2022Traded Dec 30, 2025 · filed the same day
Since the trade −58.5% · S&P 500 +7.7% · to Nov 16
Insider selling
Traded Dec 30, 2025 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −58.5% · S&P 500 +7.7% · to Nov 16
A Mustang Bio director sold $238 of Mustang Bio shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Dec 30, 2025 · filed the same dayNot reported under a pre-arranged trading plan
Since the trade −58.5% · S&P 500 +7.7% · to Nov 16
A Mustang Bio director sold $4 of Mustang Bio shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Mustang Bio reported 23 open-market purchases and 12 sales since 2018; purchases in 5 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $2381×1 trade | $2412×2 trades |
| 2022 | $12K4×4 trades | — |
| 2021 | $913K3×3 trades | $26K3×3 trades |
| 2020 | $1.59M5×5 trades | $73K6×6 trades |
| 2019 | — | $23K1×1 trade |
| 2018 | $339K10×10 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Last results
Apr 29, 2024
More than 30 days ago
Next results, expected
Mar 17, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
48%
11 of 23 insider purchases since 2017 came within 30 days after a results announcement
From Mustang Bio's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Mustang Bio's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Notice of delisting or failure to meet listing rules
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.